Patents Assigned to Allergen, Inc.
-
Patent number: 9591935Abstract: Disclosed herein are compounds having the formula (I) wherein a dashed line represents the presence or absence of a bond; Y is an organic acid functional group, or an amide or ester thereof; or Y is hydroxymethyl or an ether thereof; or Y is a tetrazolyl functional group; A is —(CH2)6—, cis —CH2CH?CH—(CH2)3—, or —CH2C?C—(CH2)3—, wherein 1 or 2 carbon atoms may be replaced by S or O; or A is —(CH2)m—Ar—(CH2)o— wherein Ar is interarylene or heterointerarylene, the sum of m and o is 1, 2, 3, or 4, and wherein 1 —CH2— may be replaced by S or O, and 1 —CH2—CH2— may be replaced by —CH?CH— or —C?C—; U1 and U2 are independently selected from —H, ?O, —OH, —F, —Cl, and —CN; and B is aryl or heteroaryl, for use as acular hypotensive agent.Type: GrantFiled: June 30, 2008Date of Patent: March 14, 2017Assignee: ALLERGEN, INC.Inventors: David W. Old, Vinh X. Ngo, Mark Holoboski, Mari Posner
-
Patent number: 9458486Abstract: Novel products comprising conditioned cell culture medium compositions and methods of use are described. The conditioned cell medium compositions of the invention may be comprised of any known defined or undefined medium and may be conditioned using any eukaryotic cell type. Once the cell medium of the invention is conditioned, it may be used in any state. Physical embodiments of the conditioned medium include, but are not limited to, liquid or solid, frozen, lyophilized or dried into a powder. Additionally, the medium is formulated with a pharmaceutically acceptable carrier as a vehicle for internal administration, applied directly to a food item or product, or formulated with a salve or ointment for topical applications. Also, the medium may be further processed to concentrate or reduce one or more factors or components contained within the medium.Type: GrantFiled: March 15, 2013Date of Patent: October 4, 2016Assignee: Allergen, Inc.Inventors: Gail K. Naughton, David L. Horwitz, Mark Applegate, Joan Zeltinger, Jonathan Mansbridge, Andreas Kern, Lee K. Landeen, Anthony Ratcliffe, R. Emmett Pinney
-
Patent number: 9089478Abstract: Viscous formulations and methods of using such compositions, useful for intramuscular and intra-articular injection are provided to treat peripheral conditions. Such compositions can include triamcinolone particles present in a therapeutically effective amount, a viscosity inducing component, and an aqueous carrier component. The compositions have viscosities of at least about 10 cps or about 100 cps at a shear rate of 0.1/second. In a preferred embodiment, the viscosity is in the range of from about 80,000 cps to about 300,000 cps. In a most preferred embodiment, the viscosity is in the range of from about 140,000 cps to about 280,000 cps at a shear rate of 0.1/second at 25° C. The compositions advantageously suspend the triamcinolone particles for prolonged periods of time.Type: GrantFiled: August 19, 2014Date of Patent: July 28, 2015Assignee: Allergen, Inc.Inventors: Scott M. Whitcup, Michael R. Robinson, Robert T. Lyons, John T. Trogden
-
Patent number: 8642067Abstract: Anti-angiogenesis compositions, and methods of using such compositions, useful for injection into the vitreous of human eyes are provided. Such compositions can include TKI component solutions or particles present in a therapeutically effective amount, a viscosity inducing component, and an aqueous carrier component. The compositions have viscosities at about 25° C. of at least about 10 cps or about 100 cps at a shear rate of 0.1/second. In a preferred embodiment, the viscosity at 25° C. is in the range of from about 80,000 cps to about 300,000 cps.Type: GrantFiled: April 2, 2007Date of Patent: February 4, 2014Assignee: Allergen, Inc.Inventors: John T. Trogden, Robert T. Lyons, James N. Chang, Scott M. Whitcup
-
Patent number: 8318169Abstract: A biocompatible, sustained release intraocular drug delivery system comprising a protein or polynucleotide therapeutic agent, a polymeric carrier for the therapeutic agent and a long chain fatty alcohol release modifier. The biocompatible, sustained release intraocular drug delivery system can be used to treat an ocular condition.Type: GrantFiled: September 12, 2011Date of Patent: November 27, 2012Assignee: Allergen, Inc.Inventors: John T. Trogden, Robert T. Lyons
-
Patent number: 8198318Abstract: Compounds comprising or a pharmaceutically acceptable salt or a prodrug thereof, are disclosed, wherein G, E, B, Y, and A are as described. Methods, compositions, and medicaments related thereto are also disclosed.Type: GrantFiled: March 16, 2009Date of Patent: June 12, 2012Assignee: Allergen, Inc.Inventors: David W. Old, Robert M. Burk, Todd Gac
-
Patent number: 8057808Abstract: Methods for treating obsessions and compulsions by local administration of a Clostridial toxin. The obsessions or compulsions can be eye poking, body rocking, finger biting, counting, checking and related disorders treated by low dose, intramuscular administration of a botulinum toxin.Type: GrantFiled: April 21, 2010Date of Patent: November 15, 2011Assignee: Allergen, Inc.Inventor: Alan H. Ackerman
-
Patent number: 7923469Abstract: Compositions for caring for contact lenses and eyes include a liquid aqueous medium and a vitamin derivative component present in an amount effective as a surfactant in the composition. The compositions can be used to clean, soak, re-wet and, with the inclusion of a disinfectant, disinfect contact lenses. In addition, the compositions are effective as artificial tears and eye wash solutions. Methods for contact lens care and eye care are also disclosed.Type: GrantFiled: April 24, 2002Date of Patent: April 12, 2011Assignee: Allergen, Inc.Inventors: Stanley Huth, Richard Chadwick, Gerry Franco
-
Patent number: 6328967Abstract: A microsphere containing an immunogen bound to an inert particle having a mesh size of greater than about 35 mesh for site-specific release and induction of an immune response. The immune response may be an overall enhanced T lymphocyte immune response or a selective response. The physical and chemical characterigticg and/or modes of administration of the microsphere may be engineered to increase TH1 lymphocytes for treatment of cancer or infectious disease. The microencapsulated immunogen has an enteric coating for oral administration.Type: GrantFiled: March 12, 1998Date of Patent: December 11, 2001Assignee: Allergenics, Inc.Inventor: Roberto L. Rivera
-
Patent number: 5643572Abstract: The present invention provides novel compositions and methods useful in the, modulation or selective suppression of host immune responses to an immunogen of interest, particularly exogenous antigens and allergens such as urushiol, the active plant component causing poison ivy/oak contact sensitivity. The subject compositions are antibody molecules of either Ab.sub.1 or Ab.sub.2 (anti-idiotypic) reactivity with respect to the sensitizing antigen. Other compositions include specific T cell receptor (TCR) molecules either as T cell clones or hybridomas or as TCR preparations. Immunogenic peptides corresponding to some or all of the complementary determining regions or hyper-variable regions of the TCR are also employed. Such compositions suppress host immune responses to antigen by a variety of pathways including anti-idiotypic interactions with cells involved in antigen processing and stimulation of the immune network.Type: GrantFiled: November 24, 1993Date of Patent: July 1, 1997Assignee: Allergene, Inc.Inventors: Vera K. Byers, Robert W. Baldwin
-
Patent number: 5512283Abstract: The present invention provides novel compositions and methods useful in the modulation or selective suppression of host immune responses to an immunogen of interest, particularly to immunogens which are exogenous antigens or allergens. Subject compositions include antibody, antibody derived, and antibody-like molecules of primary antigen reactivity with respect to the immunogen of interest. Antibodies or antibody-like or antibody-derived molecules include antibody fragments such as Fab, and complementarity determining region peptides (CDRs) which may be grafted into a framework region of any species, particularly human. They also include human antibodies, derived from sensitized human lymphocytes produced by cell fusion with heterohybridomas, or by DNA cloning and expression. Other compositions include T cell receptor (TCR) molecules, obtained either from T cell clones or hybridomas or as purified TCR preparations.Type: GrantFiled: September 16, 1993Date of Patent: April 30, 1996Assignee: Allergene, Inc.Inventors: Vera S. Byers, Robert W. Baldwin